



**ENDOSENSE NAMES JAN KELTJENS PRESIDENT AND
CHIEF EXECUTIVE OFFICER**

GENEVA – September 14, 2011 – [Endosense](#), a Swiss medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has appointed Jan Keltjens as president and chief executive officer. Keltjens brings to Endosense more than two decades of leadership experience in the medical device and technology sectors. He has previously served as chief executive officer of AngioDynamics Inc. (NASDAQ: ANGO) and CryoCath Technologies Inc. (now Medtronic CryoCath) and held a number of senior leadership positions at Cordis Corp.

Keltjens replaces outgoing President and CEO Eric Le Royer who is retiring from Endosense after leading the firm from its first venture capital financing seven years ago. Under Keltjens leadership, the company will relentlessly focus on the global commercialization of its proprietary [TactiCath](#)¹, the world's first contact-force sensing ablation catheter. As part of this effort, Endosense is rapidly enrolling patients in its [TOCCASTAR](#) investigational device exemption (IDE) clinical trial, the results of which will be used to support a Premarket Approval (PMA) filing to the U.S. Food and Drug Administration for market clearance of the TactiCath in the United States.

“Endosense is creating a breakthrough in the field of catheter ablation with its TactiCath contact-force sensing catheter, which gives physicians critical therapeutic information to improve procedure safety and effectiveness. We believe this new technology will have a profound, positive impact on clinical practice, benefitting both patients and physicians, and we are delighted that Jan has agreed to join Endosense to help the company deliver on this promise,” said Jan Egberts, chairman of the Endosense board of directors. “We would also like to thank Eric for all he has done for Endosense. Through his energy, focus and dedication, he and his team have transformed contact-force sensing from an early vision into a clinical reality and have positioned Endosense to become a leader in the rapidly growing atrial fibrillation market.”

About Endosense

Founded in Geneva in 2003, Endosense is a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias. The company pioneered the use of contact-force measurement in catheter ablation with the development of the TactiCath, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. Launched in April 2010 with a full release in September 2010, the second generation of the novel device has been used across Europe to treat more than one thousand patient cases of atrial fibrillation (AF) and supraventricular tachycardia (SVT). Endosense is currently conducting several post-market clinical studies aimed at proving the superiority of the TactiCath force-sensing catheter over standard irrigated catheters, as well as the TOCCASTAR investigational device exemption (IDE) clinical trial. Endosense has built a significant body of evidence reinforcing the value of contact-force sensing in improving patient outcomes of catheter ablation procedures. Since its first abstract on the TactiCath was presented at Heart Rhythm 2006, [more than 30 clinical publications](#) have appeared in peer-reviewed journals or been presented at major medical society meetings across the world.

Endosense is backed by Edmond de Rothschild Investment Partners, Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie. For more information, visit www.endosense.com.

¹Caution: In the United States, the TactiCath is an investigational device. Limited by Federal (or United States) law to investigational use.

ENDOSENSE MEDIA CONTACT/U.S.:
Laura Nobles
Nobles Communications
310-795-0497
laura@noblescommunications.com

ENDOSENSE MEDIA CONTACT/EUROPE:
Danièle Castle
Genevensis Communications
+41 79 202 6667
info@genevensis.com